Jeffrey Bluestone, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jeffrey Bluestone, PhD

Professor, School of Medicine, UCSF
Director, Hormone Research Institute, Diabetes Center

A.W. and Mary Margaret Clausen Distinguished Professorship in Metabolism and Endocrinology, UCSF

Jeff.Bluestone@ucsf.edu

Phone: (415) 514-0417
513 Parnassus Ave, Health Sciences West

UCSF Profiles

Cancer Center Membership

Associate Member » Cancer, Immunity, and Microenvironment

Research Summary

Jeffrey Bluestone, PhD, is the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and is the Director of the Hormone Research Institute in the Diabetes Center. His research over the past 25 years has focused on understanding the basic processes that control T cell activation and immune tolerance in autoimmunity and organ transplantation. He and members of his lab have developed soluble receptor antagonists; monoclonal antibodies and animals deficient in individual members of TCR and co-stimulatory pathways to define their individual roles in transplant rejection and autoimmunity including a special emphasis on a specialized subset of T cells termed “regulatory T cells” (Treg). Tregs control fundamental aspect of immune homeostasis. During the last several years, his research has adapted the animal studies using biologics and cell based therapies to develop therapeutics that can be used in humans with autoimmunity and under conditions of allotransplant rejection. Moreover, a strong role for antigen-specific Tregs have been found in these model systems and further evidence in humanized mice and transplant patients that alloantigen-specific Tregs are more effective. Thus, the major goal of this work is to identify the antigen-specificity of thymic- and peripherally-derived Tregs with the expectation that these TCRs can be adapted for immunotherapy. Finally, his lab initiated several projects to determine mechanisms that control Treg stability. The goal is to develop approaches using pharmacogenomics to either stabilize or destabilize Tregs in autoimmunity and cancer.

In March 2010 Dr. Bluestone was appointed executive vice chancellor and provost at the University of California San Francisco (UCSF) serving as chief academic officer guiding the research and academic enterprise advancing the campus priorities in close collaboration with the chancellor and the campus leadership teams, and to oversee the campus ethics and compliance enterprise. Previously he served in a number of posts including Director of theUCSF Diabetes Center, as Director of the Immune Tolerance Network.

In June 2008 Dr. Bluestone served as interim vice chancellor of research, directing the advancement of cross-campus research initiatives, such as enhancing core research facilities. In this capacity, he played a leading role in coordinating and integrating current research cores. He worked also to strengthen external research partnerships, particularly with industry, and focused on facilitating the translation of UCSF discoveries into public benefit.

In 2009, Dr. Bluestone led the UCSF committee to strategize and secure funds available through the American Recovery and Reinvestment Act, making the campus one of the top institutional recipients in the nation of science-based stimulus funds.

Dr. Bluestone joined the UCSF faculty in 2000. He is an international leader in the field of immunotherapy, with a stellar record of scholarly achievement and a decade of significant contributions to the research enterprise at UCSF, including the creation and directorship of an integrated UCSF Diabetes Center to focus on translating basic research in both type 1 and type 2 diabetes into improved therapies for patients. He also founded and directed the Immune Tolerance Network, a consortium of more than 1,000 of the world’s leading scientific researchers and clinical specialists from nearly 50 institutions, with the mission of testing new therapies to promote immune tolerance in transplantation, autoimmune diseases, asthma and allergic diseases.

As a research scientist, Dr. Bluestone has helped clarify the body’s immune response on a molecular level. His systematic investigation has catalyzed recent progress in stem cell research, islet cell transplantation and immune tolerance therapies – experimentation that has formidably translated into drugs to treat human disease.

Through his 30-year scientific career, he has authored more than 300 peer-reviewed publications that include prominent papers in Nature, Nature Immunology, and the Journal of Immunology and Diabetes. He has received numerous accolades for his work, including his 2006 election to the American Academy of Arts and Sciences, the Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award from the Juvenile Diabetes Research Foundation, and the distinguished alumni award from the Cornell Graduate School of Medical Science.

Prior to joining UCSF, Bluestone was at the University of Chicago, where he was a member of the Ben May Institute for Cancer Research, rising over 13 years from an associate professor to the director of the institute. He had previously worked for seven years in various roles at the National Cancer Institute of the National Institutes of Health, ultimately becoming a senior investigator in the Immunology Branch of the National Cancer Institute.

Dr. Bluestone earned both his BS in biology and his MS in microbiology from Rutgers State University, and his PhD in immunology from the Cornell Graduate School of Medical Science (Sloan-Kettering Division).

Education

Cook College, Rutgers University, B.S., 1974, Biology
Rutgers - State University, NJ, M.S., 1977, Microbiology
Cornell Graduate School of Medical Science (Sloan-Kettering Division), Ph.D., 1980, Immunology


Professional Experience

  • 1980-1982
    Anna Fuller Fund Postdoctoral Fellow, Immunology Branch, National Cancer Institute, NIH
  • 1982-1982
    Laboratory Leader, Senior Staff Fellow, Transplantation Biology Section, Immunology Branch, NCI, NIH
  • 1986-1982
    Senior Investigator, Transplantation Biology Section, Immunology Branch, NCI, NIH
  • 1987-1992
    Associate Professor, Ben May Institute, Dept. of Pathology and the Committee on Immunology, University of Chicago
  • 1991-2002
    Professor, Ben May Institute, Department of Pathology and the Committee on Immunology, University of Chicago and Chairman, Committee on Immunology
  • 1995-2002
    Director, Ben May Institute for Cancer Research
  • 1999-present
    Director, Juvenile Diabetes Center, University of Chicago and University of Minnesota
  • 1999-present
    Director, Immune Tolerance Network
  • 2000-present
    A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology; and Director, UCSF Diabetes Center, the Metabolic Research Unit and the Hormone Research Institute, UCSF

Honors & Awards

  • 1987 -1989
    Faculty Scholar, Gould Foundation
  • 1989
    Faculty Scholar, American Cancer Society
  • 1997
    Senior Fellowship, Guggenheim Foundation
  • 1997
    Senior Research Fellowship, Fogarty Foundation
  • 1998
    Distinguished Alumni Award, Cornell Medical School
  • 2004
    Gerold & Kayla Grodsky Basic Science Award, Juvenile Diabetes Research Foundation
  • 2004
    Roche Distinguished Research Award, American Society for Transplantation
  • 2005
    Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award, Juvenile Diabetes Research Foundation
  • 2006
    Elected Member, American Academy of Arts and Sciences
  • 2008
    Scholar Award, Juvenile Diabetes Research Foundation
  • 2010
    Elliott Middleton Memorial Lectureship, American Academy of Allergy, Asthma, & Immunology
  • 2013
    Elected Member, National Academy of Medicine
  • 2015
    Outstanding Mentorship Award, American Society of Transplantation
  • 2015
    President-Elect, Federation of Clinical Immunology Societies
  • 2016
    Blue Ribbon Panel on Cancer Research (Biden Moonshot Program), National Cancer Foundation

Selected Publications

  1. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016 May 17; 44(5):973-88.
    View on PubMed
  2. Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF. Correction: CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol. 2016 May 1; 196(9):3966.
    View on PubMed
  3. Gitelman SE, Bluestone JA. Regulatory T cell therapy for type 1 diabetes: May the force be with you. J Autoimmun. 2016 Jul; 71:78-87.
    View on PubMed
  4. Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia. 2016 Jun; 59(6):1153-61.
    View on PubMed
  5. DuPage M, Bluestone JA. Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol. 2016 Mar; 16(3):149-63.
    View on PubMed
  6. Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF. CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol. 2016 Mar 1; 196(5):2051-62.
    View on PubMed
  7. Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC. Inducing and Administering Tregs to Treat Human Disease. Front Immunol. 2015; 6:654.
    View on PubMed
  8. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015 Nov 25; 7(315):315ra189.
    View on PubMed
  9. Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, Bluestone JA, Burton BK, Dewey M, Freitas A, Gavin D, Griebel D, Hogan M, Holland S, Tanpaiboon P, Turka LA, Utz JJ, Wang YM, Whitley CB, Kazi ZB, Pariser AR. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab. 2016 Feb; 117(2):66-83.
    View on PubMed
  10. Holohan DR, Lee JC, Bluestone JA. Shifting the Evolving CAR T Cell Platform into Higher Gear. Cancer Cell. 2015 Oct 12; 28(4):401-2.
    View on PubMed
  11. Spence A, Klementowicz JE, Bluestone JA, Tang Q. Targeting Treg signaling for the treatment of autoimmune diseases. Curr Opin Immunol. 2015 Dec; 37:11-20.
    View on PubMed
  12. Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA, Marson A. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A. 2015 Aug 18; 112(33):10437-42.
    View on PubMed
  13. Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, Bluestone JA, Locksley RM. Interleukin-33 and Interferon-? Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation. Immunity. 2015 Jul 21; 43(1):161-74.
    View on PubMed
  14. Fuhrman CA, Yeh WI, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, Baker HV, Zhang Y, Li Y, Whitley M, von Schack D, Atkinson MA, Bluestone JA, Brusko TM. Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. J Immunol. 2015 Jul 1; 195(1):145-55.
    View on PubMed
  15. Bluestone JA, Crellin N, Trotta E. IL-2: Change Structure … Change Function. Immunity. 2015 May 19; 42(5):779-81.
    View on PubMed
  16. Bluestone JA, Bour-Jordan H, Cheng M, Anderson M. T cells in the control of organ-specific autoimmunity. J Clin Invest. 2015 Jun; 125(6):2250-60.
    View on PubMed
  17. Bluestone JA, Trotta E, Xu D. The therapeutic potential of regulatory T cells for the treatment of autoimmune disease. Expert Opin Ther Targets. 2015; 19(8):1091-103.
    View on PubMed
  18. Bluestone JA, Tang Q. Immunotherapy: making the case for precision medicine. Sci Transl Med. 2015 Mar 25; 7(280):280ed3.
    View on PubMed
  19. Villalta SA, Rosenberg AS, Bluestone JA. The immune system in Duchenne muscular dystrophy: Friend or foe. Rare Dis. 2015; 3(1):e1010966.
    View on PubMed
  20. DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, Zhang R, Turka L, Marson A, Bluestone JA. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity. 2015 Feb 17; 42(2):227-38.
    View on PubMed

Go to UCSF Profiles, powered by CTSI